Cargando…
Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis
BACKGROUND: In recent years, immune checkpoint inhibitors (ICIs) including atezolizumab, durvalumab, pembrolizumab, and nivolumab have reported their efficacy and safety profile in patients with extensive-stage small cell lung cancer (ES-SCLC). However, given the diverse efficacy and inconsistent sa...
Autores principales: | Chen, Jianxin, Wang, Junhui, Xu, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051984/ https://www.ncbi.nlm.nih.gov/pubmed/33847617 http://dx.doi.org/10.1097/MD.0000000000025180 |
Ejemplares similares
-
First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023) -
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022) -
Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials
por: Qiu, Mingliang, et al.
Publicado: (2020) -
Interleukin-10 is not associated with obstructive sleep apnea hypopnea syndrome: A meta-analysis and meta-regression
por: Li, Xiaoyan, et al.
Publicado: (2023) -
Case report: A first case of flaxseed-induced anaphylaxis in Korea
por: Kang, Yewon, et al.
Publicado: (2017)